ASH 2022
Treatment of high-risk NDMM patients and MRD-driven deescalation perspectives
GMMG-Concept, UK OPTIMUM/MUKnine Trial, Myeloma XI, RADAR UK-MRA Myeloma XV
ASH 2022
Treatment of high-risk NDMM patients and MRD-driven…
Magnetismm-3, MajesTEC-2, GO39775
ASH 2022
Bispecific antibodies - consolidating data, clinical…
Ascent Trial, GEM-CESAR
ASH 2022
Asymptomatic myeloma - what do we really want to…
CC-98633-MM-001, Atalanta-1, KarMMa-2 Cohort 2a, CARTITUDE-2 Cohort B, CC‑95266‑MM‑001
ASH 2022
CAR-T cells - manufacturing, earlier lines & new…
TRIANGLE, TARMAC
ASH 2022
Do we treat all MCL identically? New data on Ibru,…
ALPINE, BRUIN
ASH 2022
Zanu with superior PFS, Pirtobrutinib Update in R/R…
Alycante, ZUMA-7
ASH 2022
Glofi - RCHOP in 1st line, Axi-Cel in 2nd line, TMTV…
ELM-2, FLIPI24
ASH 2022
When to treat or not? Watch and wait!? Bispecifics or…
ASH 2022
NDMM highlights
DSMM XIII
ASH 2022
To transplant or not?
MRD2STOP, GEM2014MAIN, RADAR
ASH 2022
Establish MRI diagnostics early
GMMG-Concept
ASH 2022
Quadruplet for newly diagnosed high-risk patients
Myeloma XI
ASH 2022
Maintenance with lenalidomide - how long?
ASH 2022
NDMM highlights
IFM2017-03
ASH 2022
Kortikoid-Einsparung bei unfitten Patienten unter DR
MRD2STOP, GEM2014MAIN, RADAR
ASH 2022
MRD-Diagnostik früh etablieren
Myeloma XI
ASH 2022
Erhaltung mit Lenalidomid - wie lange?
GMMG-Concept
ASH 2022
Isa-KRd bei HR NDMM: Hohe MRD Negativität
ASH 2022
Bispecific antibodies highlights
MonumenTAL-1
ASH 2022
Still biting, Talquetamab?
MajesTEC-2, KarMMa-2 Cohort 2a
ASH 2022
The future of immunotherapy
GO39775
ASH 2022
Bispecific antibodies
ASH 2022
More treatment options with bispecifics emerging!
ASH 2022
CAR-T cells: new targets and early treatment
NEX-T CAR-T, Atalanta-1
ASH 2022
New CAR-T technologies
Nex-T CAR-T
ASH 2022
New generation CAR-T cell therapy with fast…
MonumenTAL-1
ASH 2022
GPRC5D-immunotherapy
ASH 2022
Bispecific antibodies highlights
NEX-T CAR-T, Atalanta-1
ASH 2022
Nye CAR-T-teknologier
GO39775
ASH 2022
Bispesifikke antistoffer
ASH 2022
Bispezifische Antikörper: Weitere Behandlungsoptionen…
Nex-T CAR-T
ASH 2022
Neue Generation der CAR-T Zelltherapie mit schneller…
MajesTEC-2, KarMMa-2 Cohort 2a
ASH 2022
Die Zukunft der Immuntherapie
ASH 2022
CAR-T Zellen: Neue erfolgsversprechende Targets und…
MonumenTAL-1
ASH 2022
GPRC5D immunterapi
GEM-CESAR, ASCENT
ASH 2022
Smouldering myeloma - potentially curable?
ASH 2022
Plasma cells aren't alone!
GEM-CESAR, ASCENT
ASH 2022
Smouldering Myelom – potentiell heilbar?
ASH 2022
Glofitamab demonstrates high efficacy in r/r MCL
VALERIA
ASH 2022
VALERIA response-adapted treatment for R/R MCL patients
ASH 2022
Glofitamab in R/R mantle cell lymphoma
Tarmac
ASH 2022
Early use of anti-CD19 CAR-T (tisacel) plus ibrutinib…
Triangle
ASH 2022
Ibrutinib + Ctx replaces autologous stem cell…
Triangle
ASH 2022
Ibrutinib combined with chemotherapy could replace ASCT
Triangle
ASH 2022
Ibrutinib added in induction and maintenance improves…
ASH 2022
The R2-Acalabrutinib combination in first-line is…
ASH 2022
Fixed-duration Glofitamab produces high quality and…
Triangle
ASH 2022
TRIANGLE - addition of Ibrutinib will improve outcome…
ASH 2022
Glofitamab för recidiverande MCL
Tarmac
ASH 2022
El uso precoz de CAR-T anti-CD19 (tisacel) e ibrutinib…
Triangle
ASH 2022
Ibrutinib en inducción y mantenimiento mejora la…
ASh 2022
Glofitamab en esquema fijo de 12 meses produce…
VALERIA
ASH 2022
Valeria- responsstyrd behandling för recidiverande MCL
ASH 2022
El triplete R2-Acalabrutinib en primera línea es…
Triangle
ASH 2022
Ibrutinib + Ctx ersetzt autologe…
Triangle
ASH 2022
TRIANGLE- tillägg av ibrutinib förbättrar…
ELM-2
ASH 2022
Odronextamab in relapsed/refractory follicular lymphoma
FLIPI24
ASH 2022
A new FLIPI to predict POD24 in follicular lymphoma
Elara Trial
ASH 2022
Tisagenlecleucel at r/r FL: convincing response more…
ASH 2022
Is watch & wait still valualble in follicular lymphoma?
ASH 2022
Watch and Wait remains standard of care
EPCORE NHL-2 arm 2b
ASH 2022
Bispecific antibody Epcoritamab s.c. + R2 convincing
EPCORE NHL-2 arm 2b
ASH 2022
Epcoritamab - bispecific antibody highly effective in…
ASH 2022
E' ancora valido il watch & wait nel linfoma…
FLIPI24
ASH 2022
Un nuovo FLIPI per predire la POD24 nel linfoma…
EPCORE NHL-2 arm 2b
ASH 2022
Epcoritamab-R2 nel linfoma follicolare…
ASH 2022
Watch and Wait bleibt Standard
Elara Trial
ASH 2022
Tisagenlecleucel beim r/r FL: Überzeugendes Ansprechen…
ELM-2
ASH 2022
Odronextamab nel linfoma follicolare…
EPCORE NHL-2 arm 2b
ASH 2022
Bispezifischer Antikörper Epcoritamab s.c. + R2…
Alycante
ASH 2022
Alycante - axi-cel in transplant-ineligible R/R DLBCL…
Alycante
ASH 2022
Two highlight studies in DLBCL treatment
Alycante
ASH 2022
Deux études marquantes dans le traitement du DLBCL
Alycante
ASH 2022
Alycante - axi-cel till patienter med tidigt recidiv av…
ASH 2022
Ventricular arrhythmias under combination ibrutinib +…
ASH 2022
Ventrikuläre Arrhythmien unter Kombi Ibrutinib +…
BRUIN
ASH 2022
Pirtobrutinib shows activity in pre-treated r/r…
ALPINE
ASH 2022
Zanubrutinib demonstrates superiority in r/r CLL/SLL
Neutrodiet
ASH 2022
Is it time to feed our patients?
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!